See the list of featured NIAID clinical trials below or view the complete list of NIAID studies recruiting participants on ClinicalTrials.gov.
244 Results
A Biorepository of Multiple Allergic Diseases (MADREP) With Longitudinal Follow-Up
To create a repository of clinical, laboratory, and diagnostic data and specimens from a cohort of suspected or confirmed atopic or allergic individuals with diverse disorders seen by allergist-immunologists and rhinologists.
A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission
This study is a phase II, two-arm, randomized, double-blind, placebo-controlled study that will enroll 48 antiretroviral therapy (ART)-naïve adults with acute HIV infection (AHI).
A Clinical Trial to Evaluate the Safety and Immunogenicity of CH505M5 N197D mRNA-gp160 Followed by CH505 TF mRNA-gp160 in Adults in Overall Good Health Without HIV
The objective of this study is to evaluate the safety and immunogenicity of CH505M5 N197D mRNA-gp160 and CH505 TF mRNA-gp160.
A Comprehensive Clinical, Microbiological and Immunological Assessment of Patients With Suspected Post Treatment Lyme Disease Syndrome and Selected Control Populations
The purpose of this study is to determine whether patients who have been infected with the Lyme bacteria, Borrelia burgdorferi, and treated with antibiotics still have the bacteria alive inside them and whether it is causing their symptoms.
A Deep Longitudinal Analysis of Next Generation Influenza Vaccines in Older Adults
This is a prospective, single-arm study designed to understand the mechanisms that lead to a loss of response to influenza vaccine in older adults.
A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression
The purpose of this study is to investigate FE and its genetic causes, damage mechanisms, and disease markers (such as blood test abnormalities).
A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa
This is a phase 1b/2 study of a single dose of intravenous (IV) bacteriophage in males and non-pregnant females, at least 18 years old, diagnosed with Cystic Fibrosis (CF).
A phase 2 open-label study to evaluate the efficacy and safety of ruxolitinib on hair regrowth in patients with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED)- associated alopecia areata
The purpose of this study is to see if a study drug (ruxolitinib) can help hair regrowth in people with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED)-associated alopecia areata (AA) and if it can improve other symptoms caused by the immune system s attack to the body.
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
The purpose of this study is to evaluate whether Mozobil is safe and effective to treat neutropenia (low white blood cell count) in patients with WHIMS and to determine an appropriate treatment dose of Mozobil, within currently approved dosage levels.
A randomized placebo-controlled study to evaluate the safety and effects of repeated doses of 3BNC117-LS and 10-1074-LS on persistent viral reservoirs in people living with HIV and on suppressive antiretroviral therapy (LONGBNAB)
The purpose of this research study is to evaluate whether three doses of the two study drugs being tested, 3BN117-LS and 10-1074-LS, are safe and tolerable. This study will also evaluate if the study drugs change the numbers of blood cells that are infected with HIV while you are on antiretroviral therapy (ART). This pool of blood cells that contain dormant HIV is referred to as the persistent viral reservoir.
A Repository to Study Host-Microbiome Interactions in Health and Disease
The purpose of this study is to collect microbiome samples from the body that can be used for future research.
A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus
The primary objective of this study is to determine the systemic exposure (AUC24) of letermovir following administration of oral letermovir granules in infants with symptomatic congenital Cytomegalovirus (CMV) disease.
A Single arm Open Label Phase 2 trial of anti-CD4 Antibody UB-421 in Combination with Optimized Background Antiretroviral Therapy in Patients with Multi-Drug Resistant HIV-1 (UB-421)
The purpose of this study is: (1) to see if a drug called UB-421 is able to control human immunodeficiency virus (HIV) in patients with a virus that has become so resistant to anti-HIV drugs that an effective treatment regimen cannot be put together using drugs currently approved by the US Food and Drug Administration (FDA); and (2) to see if UB-421 is safe for patients with multiple-drug resistant HIV.
A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia
The purpose of this study is to test a new drug (NT-17) in people with idiopathic CD4 lymphopenia (ICL) which can increase the number of CD4 T cells.
A Study of Doxycycline to Treat Chlamydial Infection
The primary objective of this study is to compare the efficacy of a 3-day vs. 7-day regimen of doxycycline for treatment of urogenital chlamydia (CT) infection in the specified participants.
A Study of Standard Drugs for Mycobacterium Avium Complex
To assess the early bactericidal activity of Azithromycin 250mg by mouth daily over the first 14 days of treatment for Mycobacterium avium complex (MAC) lung disease.
A Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1
This study will test an anti-HIV drug (ARV) for newborn babies.
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects with Hepatic Impairment and in Healthy Subjects with Normal Hepatic Function
The primary purpose of this study is to characterize the effect of hepatic impairment on the plasma pharmacokinetics of ALG-097558 following administration of multiple, twice daily (Q12H) oral (PO) doses.
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects with Renal Impairment and in Healthy Subjects with Normal Renal Function
The primary purpose of this study is to characterize the effect of renal impairment on the plasma pharmacokinetics of ALG-097558 following administration of multiple, twice daily (Q12H) oral (PO) doses.
A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults
The primary objective of this study is to assess the safety of two doses of DCVC H1 HA mRNA vaccine administered intramuscularly in healthy adults (18-49 yrs) at dosage levels of 10 mcg, 25 mcg, and 50 mcg.
Activation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia
This study will investigate how, why and under what conditions eosinophils (a type of white blood cell) become activated and will examine their function in immune reactions.
Admission and Management of Occupational or Other Exposures to Biodefense/Bioterrorism Agents or to Epidemic/Emerging Infectious Diseases
The objective of this study is to apply standardized, documented, and carefully monitored evaluation and treatment methods for bioterrorism- and biodefense-related illnesses and emerging infectious diseases at the National Institutes of Health Clinical Center.
Adolescent Master Protocol for Participants 18 Years of Age and Older (AMP Up)
This is a prospective cohort study designed to define the impact of HIV infection and antiretroviral therapy (ART) on young adults with perinatal HIV infection (YAPHIV) as they transition into adulthood. A group of of perinatally exposed but uninfected young adults from a similar sociodemographic background and age distribution will be enrolled for comparison.
Advancing Transplantation Outcomes in Children
This is a pediatric kidney transplant study comparing the safety and efficacy of an immunosuppressive regimen of belatacept and sirolimus to tacrolimus and Mycophenolate Mofetil (MMF).
Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists
The purpose of the summary is to find out if a different drug treatment can improve the success rates of stem cell transplants in people with chronic granulomatous disease (CGD).